BCL2 mutations do not confer adverse prognosis in follicular lymphoma patients treated with rituximab.
Am J Hematol
; 92(6): 515-519, 2017 Jun.
Article
en En
| MEDLINE
| ID: mdl-28247997
ABSTRACT
BCL2 mutations have been suggested to confer an adverse prognosis to follicular lymphoma (FL) patients, but their prognostic value has not been assessed in patients treated with a rituximab-containing regimen. Here we evaluated the prognostic value of BCL2 mutations in a large prospective cohort of 252 patients with FL treated with immunochemotherapy in the PRIMA randomized trial. Using a DNA-targeted sequencing approach, we detected amino acid altering mutations in 135 patients (54%) and showed that these mutations were probably mediated by the over-activation of AICDA (activation-induced cytidine deaminase) in the context of the t(14;18) translocation. The BCL2 variants identified in PRIMA patients affected the BH1, BH2, and BH3 functional motifs at a lower frequency than the N-terminus and flexible loop domain, with mostly conservative aminoacid changes. With a median follow-up of 6.7 years, we did not observe any impact of BCL2 mutations either on overall survival or progression-free survival.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Linfoma Folicular
/
Proteínas Proto-Oncogénicas c-bcl-2
/
Mutación
Tipo de estudio:
Clinical_trials
/
Prognostic_studies
Límite:
Female
/
Humans
/
Male
Idioma:
En
Revista:
Am J Hematol
Año:
2017
Tipo del documento:
Article
País de afiliación:
Francia